Aim: Malignant melanoma is the most frequent skin cancer in childrenand adolescents. It comprises 1–3% of all malignancies. In this study,we aimed to evaluate the clinical aspects, histopathologic features, andtreatment outcomes of our patients with malignant melanoma.Material and Methods: Patients aged <15 years who were treated between 2003 and 2018 for malignant melanoma were retrospectively analyzed.Results: Seventeen patients (10 females, 7 males), with a median ageof 7 years (range, 7 months-13 years) were evaluated. Five patients hadcongenital melanocytic nevi. All had cutaneous melanoma except onewith mucosal (conjunctival) melanoma. The most frequent primarytumor site was the lower extremities (35%). Sentinel lymphoscintigraphy, sentinel node biopsy, and PET/CT were performed as the stagingprocedures at initial diagnosis. Localized disease was present in eightpatients; nine had regional lymph node metastasis. The only treatmentwas surgery in localized disease; surgery and adjuvant interferon treatment was given in patients with regional lymph node metastasis. Threedeveloped distant metastasis (bone, lung, brain) at a median of 9 months.A three-year-old patient received a BRAF inhibitor (vemurafenib), and a13-year-old patient received a check point inhibitor (ipilimumab); bothdied of progressive disease. The median follow-up for all patients was 25months. The 5-year overall survival was 76.6%.Conclusion: Although malignant melanoma is rare in children, prognosisis good if diagnosed early. Physicians should be aware of skin lesions andfull-layer biopsy should be obtained in suspicious skin lesions. Patientswith congenital melanocytic nevi should also be followed up cautiously